Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07900061

Title field or adapter rule

{'original_value': 'Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:09.756905+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-11-01T01:03:09.151179+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Rectal Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07900061"

protocolSection.identificationModule.officialTitle

"Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Rectal Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['node-sparing modified short course radiotherapy combined with tislelizumab and CAPOX'], 'description': 'Study participants receive modified short-course radiotherapy to the rectum for 5 days. The radiation field covers the primary rectal tumor region, excluding regional lymphatic drainage areas, with a total radiation dose of 25 Gy (5 Gy per fraction × 5 fractions). On Day 8 after radiotherapy initiation, participants receive combination therapy with CAPOX (Oxaliplatin 130 mg/m², ivgtt on Day 1; Capecitabine 1000 mg/m², bid po from Day 1 to Day 14; q3w) and tislelizumab (200 mg, ivgtt on Day 1; q3w). Treatment cycles are repeated every 3 weeks for a total of 4 cycles.', 'name': 'node-sparing modified short-course radiotherapy', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['standard short course radiotherapy combined with CAPOX'], 'description': 'Study participants receive standard short-course radiotherapy for 5 days. On Day 8 after radiotherapy initiation, participants receive CAPOX (Oxaliplatin 130 mg/m², ivgtt on Day 1; Capecitabine 1000 mg/m², bid po from Day 1 to Day 14; q3w). Treatment cycles are repeated every 3 weeks for a total of 4 cycles.', 'name': 'standard short-course radiotherapy', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.